niftify.in

The Economic Times

Linking spurious drugs with legitimate manufacturers has severe reputational, financial impact: IPA

The Indian Pharmaceutical Alliance (IPA) has called for a clear distinction between spurious and sub-standard drugs following a CDSCO report listing over 50 products as 'not of standard quality'. Major drug firms like Sun Pharma and Glenmark assert that flagged medicines are counterfeits, not their products. IPA emphasizes the need to protect India's reputation as a reliable medicine supplier.

CNBC TV18

Glenmark Pharma: Ashish Dhawan portfolio stock surges 9% as USFDA clears Aurangabad unit

Brokerage firm Investec expects that earnings momentum, along with strong cash flow generation, will continue to support the company's ongoing re-rating.

Business Standard

Glenmark Pharma's Maharashtra facility clears USFDA inspection

Glenmark Pharmaceuticals has announced that its formulation manufacturing facility located in Chhatrapati Sambhaji Nagar (Aurangabad), Maharashtra, has successfully cleared the US Food and Drug Administration (USFDA) inspection with zero observations

Business Standard

Glenmark Pharma successful concludes USFDA inspection of its Aurangabad unit

Powered by Capital Market - Live News

CNBC TV18

Glenmark Pharma Aurangabad unit clears FDA test

The United States FDA inspection, conducted between September 9-20, concluded with the issuance of a Form 483, with zero observations. Shares of Glenmark Pharmaceuticals Ltd ended at ₹1,635, down by ₹16.15, or 0.98%, on the BSE.

Mint

Glenmark, JB Pharma, Sun, Zydus Lifescience drive pharma market growth in August

Stock Market Today: The Nifty Pharma Index has gained around 37% year to date. The earnings growth for firms is being led by the US sales and well supported by domestic market that grew 7.6% year on year in August'24. Glenmark, JB Pharma, Sun, Zydus were key pharma market growth drivers in August'24

The Economic Times

Technical Breakout Stocks: How to trade Hindustan Unilever, Jubilant Pharmova and Glenmark Life on Tuesday?

Indian markets ended higher on Monday, with the S&P BSE Sensex up over 370 points and Nifty50 maintaining 24,900 levels. Gains were seen in consumer durables, banks, and FMCG, while sectors like PSU and energy saw declines.

Business Standard

Domestic formulations biz expected to grow 9-10% over next decade: Glenmark

The drug formulations market in India is expected to grow at a CAGR of 9-10 per cent over the next decade with Jan Aushadhi outlets anticipated to emerge as a much stronger player in the country, according to Glenmark Pharmaceuticals. The domestic formulations market is estimated to be at Rs 2 lakh crore, with a growth rate of 11 per cent over the past two decades. "It is projected that the domestic formulations market will maintain a compound annual growth rate (CAGR) of 9-10 per cent over the next decade," the Mumbai-based drug maker said in its Annual Report for 2023-24. As the Trade Generics and Jan Aushadhi channels expand, it is anticipated that these channels could collectively contribute 30 per cent to the market volume in ten years, it stated. The Jan Aushadhi initiative aims to enhance access to cost-effective, unbranded generics by scaling up to 25,000 franchise pharmacies by 2026, it said. "It is estimated that Jan Aushadhi procurement could account for 3-5 per cent o

The Economic Times

Technical Breakout Stocks: How to trade Glenmark Pharma, Piramal Pharma and Suven Life on Monday

The Indian market closed in the red for the fourth consecutive day, with the Sensex falling over 1,000 points and Nifty50 below 24,900. Despite this, Glenmark Pharma, Piramal Pharma, and Suven Pharma showed positive trends. Analysts suggest a bullish outlook for these stocks based on recent technical indicators.

Business Standard

Glenmark to pay $25 million as part of settlement with US authorities

Glenmark Pharmaceuticals has agreed to pay USD 25 million as part of a settlement with the US Department of Justice regarding a case related to the pricing of a generic drug. Glenmark Pharmaceuticals Inc, USA, a wholly-owned subsidiary of the Mumbai-based drug maker, has agreed to pay the amount in six installments over five years, with interest on the settlement amount at a rate of 4.25 per cent per annum from May 28, 2024, the company said in a late night regulatory filing on Wednesday. The Civil Division of the US Department of Justice has concluded its False Claims Act and Anti-Kickback Statute investigation in a settlement with Glenmark Pharmaceuticals Inc, USA, it said. "The settlement amount and interest on the settlement amount constitute restitution," the drug maker said. As noted, the settlement does not contain any admission of liability by the company, except to the extent already admitted by Glenmark in the August 2023 Deferred Prosecution Agreement, it added. Last ye

CNBC TV18

Glenmark Pharma to pay $25 million over five years to settle US investigations

The settlement signed by Glenmark pertains to the False Claims Act and the Anti Kickback investigation against the company.

The Economic Times

​Technical Breakout Stocks: How to trade Glenmark Pharma, Oil India and MCX on Monday

Sectorally, buying was seen in utilities, healthcare, and realty stocks.

Business Standard

Globus Spirits Ltd leads gainers in 'A' group

Triveni Engineering and Industries Ltd, Shree Renuka Sugars Ltd, Patel Engineering Ltd and Glenmark Life Sciences Ltd are among the other gainers in the BSE's 'A' group today, 30 August 2024.

Business Standard

Aurobindo, others recall products in US market over production issue: USFDA

Drug makers Aurobindo Pharma, Glenmark and FDC are recalling products in the US due to manufacturing issues, as per the US Food and Drug Administration (USFDA). Aurobindo Pharma USA Inc -- a unit of Hyderabad-based drug major -- is recalling 240 bottles of pain-relieving medication Healthy Living Acetaminophen, Aspirin (NSAID) and caffeine tablets. As per the latest enforcement report of USFDA, the company is recalling the affected lot due to "Missing Label". Some bottles are missing the manufacturer's label that includes the drug facts information, the US health regulator said. The New Jersey-based Aurobindo Pharma USA Inc initiated the Class 1 recall on July 11, it said. As per the US health regulator, a Class I recall pertains to defective products that can cause serious health problems. Similarly, a US-based subsidiary of Glenmark Pharmaceuticals is recalling 2,404 bottles of Indomethacin Extended-Release Capsules, produced at a Madhya Pradesh plant, due to "Failed Dissolutio

The Economic Times

Aurobindo, Glenmark, FDC recall products in US market over manufacturing issues: USFDA

The New Jersey-based Aurobindo Pharma USA Inc initiated the Class 1 recall on July 11, it said. As per the US health regulator, a Class I recall pertains to defective products that can cause serious health problems. Similarly, a US-based subsidiary of Glenmark Pharmaceuticals is recalling 2,404 bottles of Indomethacin Extended-Release Capsules, produced at a Madhya Pradesh plant, due to "Failed Dissolution Specifications", USFDA said.

Business Standard

Glenmark Pharma Q1 results: Profit increases to Rs 462 cr on strong demand

The drugmaker reported consolidated profit before exceptional items and taxes of Rs 462 crore ($55 million) for the quarter ended June 30, from Rs 203 crore a year ago

The Economic Times

Glenmark Q1 Results: Net profit doubles to Rs 340 crore

Glenmark Pharma net profit doubled to Rs 340 crore crore in Q1FY25 led by robust sales growth in India and Europe and reduction in finance, depreciation and ammortisation costs.

Business Standard

Glenmark Pharma receives USFDA approval for seizure treatment drug

The approval by the US Food & Drug Administration (USFDA) is for Topiramate capsules of strengths 15 mg and 25 mg, Glenmark Pharmaceuticals said in a statement

Business Line

Glenmark Life Sciences dips on Glenmark Pharma’s plan to exit

Development comes about 10 months after Glenmark Pharma sold 75 percent stake in GLS to Nirma

Business Line

Stocks that will see action today: July 11, 2024

Buzzing stocks: SBI, UltraTech, Zydus Life, Indo Wind, Sona BLW, Glenmark Pharma, Glenmark Life, IdeaForge, PowerGrid, Oriana Power

Business Standard

Glenmark Pharmaceuticals to sell 7.84% stake in Glenmark Life Sciences

The specific price and date of the offer for sale will likely be announced in the future